Firebrick Pharma Ltd

Healthcare AU FRE

0.058AUD
-0.012(17.14%)

Last update at 2024-05-29T01:12:00Z

Day Range

0.060.06
LowHigh

52 Week Range

0.040.36
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.80207M -3.79631M -2.43904M -1.49848M -0.72526M
Minority interest - - - - -
Net income -6.80207M -3.79631M -2.43904M -1.49848M -0.72526M
Selling general administrative 2.76M 0.50M 1.73M 0.38M 0.12M
Selling and marketing expenses - 0.33M - - -
Gross profit 0.00083M 0.00412M - - -
Reconciled depreciation 0.00952M 0.00694M - - -
Ebit -6.75187M -3.79217M -2.43980M -1.49900M -
Ebitda -6.85422M -3.78523M - - -
Depreciation and amortization - 0.00694M - - -
Non operating income net other - - - - -
Operating income -6.86374M -3.79217M -2.86180M -2.00798M -1.17337M
Other operating expenses 0.19M 4.88M 0.07M 0.07M -
Interest expense - 0.00414M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.04M 0.00128M 0.00076M 0.00052M 0.00314M
Net interest income 0.04M -0.00286M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 1.08M - - -
Total revenue 0.00083M 0.00412M 0.00000M 0.00000M 0.00000M
Total operating expenses - 4.88M - - -
Cost of revenue - - - - -
Total other income expense net 0.02M 1.08M - - -
Discontinued operations - - - - -
Net income from continuing ops -6.80207M -3.79631M - - -
Net income applicable to common shares -6.80207M -3.79631M -2.43904M -1.49848M -0.72526M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 2.98M 8.73M 11.77M 0.65M 1.18M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.10M 0.00535M 0.01M - -
Total liab 0.51M 0.45M 0.21M 0.26M 0.10M
Total stockholder equity 2.48M 8.28M 11.55M 0.39M 1.08M
Deferred long term liab - - - - -
Other current liab 0.17M 0.41M 0.08M - -
Common stock 17.07M 16.00M 15.99M 2.66M 2.09M
Capital stock 17.07M 16.00M 15.99M - -
Retained earnings -15.57866M -8.80510M -5.23911M -2.59475M -1.00618M
Other liab - - - - -
Good will - - - - -
Other assets 0.36M 0.36M 0.08M - -
Cash 2.35M 7.14M 10.88M 0.09M 0.58M
Cash and equivalents - - - - -
Total current liabilities 0.51M 0.45M 0.21M 0.21M 0.04M
Current deferred revenue - - - - -
Net debt - -7.14290M -10.87588M - -
Short term debt 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 0.99M 1.08M 0.81M 0.33M -
Property plant equipment 0.03M 0.04M 0.02M 0.00060M 0.00091M
Total current assets 2.59M 8.33M 11.68M 0.65M 1.18M
Long term investments - - - - -
Net tangible assets 2.48M 8.28M 1.55M 0.39M -
Short term investments - - 0.28M - -
Net receivables 0.14M 1.08M 0.50M 0.56M -
Long term debt - - - - -
Inventory - 0.10M - - -
Accounts payable 0.20M 0.04M 0.14M 0.20M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 1.08M 0.81M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.36M 0.36M 0.08M - -
Deferred long term asset charges - - - - -
Non current assets total 0.39M 0.40M 0.09M - -
Capital lease obligations - - - - -
Long term debt total 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.00162M -0.03254M - - -
Change to liabilities 0.06M 0.20M -0.07110M 0.17M -
Total cashflows from investing activities -0.00162M -0.03254M -0.01607M -0.01607M -
Net borrowings - - - - -
Total cash from financing activities 1.00M 10.23M 3.01M 0.50M 1.26M
Change to operating activities 0.00711M -0.05015M -0.01275M 0.09M -
Net income -6.80207M -3.79631M -2.43904M -1.49848M -
Change in cash -4.78832M 5.99M 1.06M -0.48476M 0.19M
Begin period cash flow 7.14M 1.15M - - -
End period cash flow 2.35M 7.14M 1.15M - -
Total cash from operating activities -5.78336M -4.20223M -1.93610M -0.98501M -1.06447M
Issuance of capital stock 1.00M 10.70M - - -
Depreciation 0.00952M 0.00694M 0.00052M 0.00030M -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - -0.28324M -0.28324M -0.28324M -
Change to account receivables 0.94M -0.57849M 0.05M -0.05223M -
Sale purchase of stock 1.00M -0.47408M 3.13M 0.41M 0.69M
Other cashflows from financing activities -0.00626M 0.11M -0.11637M -0.11637M 0.57M
Change to netincome 0.00211M 0.30M 0.53M 0.30M -
Capital expenditures 0.00162M 0.03M 0.02M 0.02M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -4.25429M -2.80772M -1.53630M -0.98501M -1.09742M
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow -5.78497M -0.03254M - - -

Fundamentals

  • Previous Close 0.07
  • Market Cap12.55M
  • Volume41364
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.50300M
  • Revenue TTM1.82M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 0.02M
  • Diluted EPS TTM-0.02

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FRE
Firebrick Pharma Ltd
-0.012 17.14% 0.06 - - 5.22 5.97 4.56 -1.7716
MYX
Mayne Pharma Group Ltd
-0.12 2.33% 5.04 - 285.71 1.88 1.10 1.79 -5.809

Reports Covered

Stock Research & News

Profile

Firebrick Pharma Limited engages in the development and partnering of broad-spectrum antimicrobial spray for the treatment of common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.

Firebrick Pharma Ltd

440 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Peter Laurence Molloy BSc, FAICD, MBA Founder, Exec. Chairman & CEO 1954
Dr. Stephen Francis Goodall MASc, MBA Founder, COO & Exec. Director NA
Mr. Kavi Bekarma B.Sc., C.A. Chief Financial Officer NA
Dr. Simon Tucker Chief Scientific Officer NA
Ms. Robyn Branigan Head of Marketing NA
Prof. Peter Friedland Chief Medical Officer NA
Dr. Monique Baldwin Head of Regulatory Affairs NA
Ms. Kyla Garic Exec. Officer NA
Mr. Stephen Buckley Company Sec. NA
Dr. Peter Laurence Molloy BSc, FAICD, MBA Founder, Executive Chairman & CEO 1954

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).